A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
Bendell, Johanna C., Kurkjian, Carla, Infante, Jeffrey R., Bauer, Todd M., Burris, Howard A., Greco, F. Anthony, Shih, Kent C., Thompson, Dana S., Lane, Cassie M., Finney, Lindsey H., Jones, Suzanne FVolume:
33
Langue:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-015-0218-6
Date:
April, 2015
Fichier:
PDF, 1.07 MB
english, 2015
File converter
Plus de résultats de recherche
More benefits 
